Drugs / AAVLK03hOTC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05092685 | Nov 2023 → Jun 2026 overdue | ornithine carbamoyltransferase deficiency | University College, London | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAVLK03hOTC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05092685 ↗ |
| Known as | ssAAV-LK03.hAAT.hcoOTC | “AAVLK03hOTC (also known as ssAAV-LK03.hAAT.hcoOTC)” NCT05092685 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “new gene therapy (AAVLK03hOTC)” NCT05092685 ↗ |
| Route | Intravenous | “Peripheral intravenous infusion of AAVLK03hOTC.” NCT05092685 ↗ |